Tags

Type your tag names separated by a space and hit enter

Evaluation of a commercial immunoassay for autoantibodies in Chinese Han systemic sclerosis population.
Clin Chim Acta. 2019 Apr; 491:121-125.CC

Abstract

OBJECTIVE

The autoantibody profile, which varies between races, has rarely been reported in Chinese Han systemic sclerosis (SSc) patients. The present study aims to investigate the autoantibody profile of Chinese Han SSc patients using a commercial line immunoassay.

METHODS

The prevalence of autoantibodies to Ro-52, PDGFR, Ku, PM75, PM100, Th/To, NOR90, Fib, RP155, RP11, CENP-B, CENP-A and Scl-70 were analyzed in serum samples obtained from healthy controls (n = 30), SSc patients (n = 320) and non-SSc connective-tissue disease patients (n = 100) using an Euroline Systemic Sclerosis Profile kit.

RESULTS

SSc patients had increased prevalence of anti-RP11 (P = 0.032), anti-CENPB (P < 0.001), anti-CENPA (P = 0.001) and anti-Scl-70 (P < 0.001), but had decreased prevalence of anti-Ro-52 (P = 0.004), when compared to non-SSc CTDs. Furthermore, SSc patients had increased prevalence of anti-Ro-52 (P = 0.003), anti-CENPB (P = 0.034), anti-CENPA (P = 0.034) and anti-Scl-70 (P < 0.001), when compared to HCs. In addition, SSc patients with interstitial lung disease (ILD) had increased prevalence of anti-Ro-52 (P = 0.046) and anti-Scl-70 (P = 0.035), but had decreased prevalence of anti-CENPB (P < 0.001) and anti-CENPA (P < 0.001). Moreover, SSc patients with pulmonary arterial hypertension (PAH) had increased prevalence of anti-Ro-52 (P = 0.013) and decreased prevalence of anti-Scl-70 (P = 0.001). Anti-Ro-52 and anti-Scl-70 had increased values for predicting ILD in SSc patients, while anti-Ro-52 had increased values for predicting PAH in SSc patients.

CONCLUSION

A commercial line immunoassay was used to evaluate the diagnostic value of autoantibodies in Chinese Han SSc patients. The results clearly indicate that the immunoblot assay has good diagnostic utility for SSc. Anti-Ro-52, anti-RP11, anti-CENPB, anti-CENPA and anti-Scl-70 are useful for diagnosing SSc in the Chinese Han population. Anti-Ro-52, anti-CENPB, anti-CENPA and anti-Scl-70 have a potential value for diagnosing ILD in SSc patients. Furthermore, anti-Ro-52 and anti-Scl-70 may be used to diagnose PAH in SSc patients.

Authors+Show Affiliations

Department of Clinical Laboratory, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China.Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences & Peking Union Medical College, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Peking Union Medical College Hospital, Beijing 100730, China.Department of Clinical Laboratory, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China; EUROIMMUN Academy, EUROIMMUN Medical Diagnostic (China) Co., Ltd, Beijing 100101, China.Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences & Peking Union Medical College, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Peking Union Medical College Hospital, Beijing 100730, China.Department of Clinical Laboratory, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China.Department of Clinical Laboratory, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China; Department of Clinical laboratory, Peking University International Hospital, Beijing 102206, China.Department of Clinical Laboratory, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China.Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences & Peking Union Medical College, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Peking Union Medical College Hospital, Beijing 100730, China.Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences & Peking Union Medical College, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Peking Union Medical College Hospital, Beijing 100730, China.Department of Clinical Laboratory, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China. Electronic address: yongzhelipumch@126.com.

Pub Type(s)

Evaluation Study
Journal Article

Language

eng

PubMed ID

30685360

Citation

Liu, Chenxi, et al. "Evaluation of a Commercial Immunoassay for Autoantibodies in Chinese Han Systemic Sclerosis Population." Clinica Chimica Acta; International Journal of Clinical Chemistry, vol. 491, 2019, pp. 121-125.
Liu C, Hou Y, Yang Y, et al. Evaluation of a commercial immunoassay for autoantibodies in Chinese Han systemic sclerosis population. Clin Chim Acta. 2019;491:121-125.
Liu, C., Hou, Y., Yang, Y., Xu, D., Li, L., Li, J., Wen, X., Zeng, X., Zhang, F., & Li, Y. (2019). Evaluation of a commercial immunoassay for autoantibodies in Chinese Han systemic sclerosis population. Clinica Chimica Acta; International Journal of Clinical Chemistry, 491, 121-125. https://doi.org/10.1016/j.cca.2019.01.020
Liu C, et al. Evaluation of a Commercial Immunoassay for Autoantibodies in Chinese Han Systemic Sclerosis Population. Clin Chim Acta. 2019;491:121-125. PubMed PMID: 30685360.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Evaluation of a commercial immunoassay for autoantibodies in Chinese Han systemic sclerosis population. AU - Liu,Chenxi, AU - Hou,Yong, AU - Yang,Yajun, AU - Xu,Dong, AU - Li,Liubing, AU - Li,Jing, AU - Wen,Xiaoting, AU - Zeng,Xiaofeng, AU - Zhang,Fengchun, AU - Li,Yongzhe, Y1 - 2019/01/24/ PY - 2018/05/23/received PY - 2018/10/11/revised PY - 2019/01/22/accepted PY - 2019/1/28/pubmed PY - 2019/3/19/medline PY - 2019/1/28/entrez KW - Autoantibody KW - Connective-tissue disease KW - Interstitial lung disease KW - Pulmonary arterial hypertension KW - Systemic sclerosis SP - 121 EP - 125 JF - Clinica chimica acta; international journal of clinical chemistry JO - Clin Chim Acta VL - 491 N2 - OBJECTIVE: The autoantibody profile, which varies between races, has rarely been reported in Chinese Han systemic sclerosis (SSc) patients. The present study aims to investigate the autoantibody profile of Chinese Han SSc patients using a commercial line immunoassay. METHODS: The prevalence of autoantibodies to Ro-52, PDGFR, Ku, PM75, PM100, Th/To, NOR90, Fib, RP155, RP11, CENP-B, CENP-A and Scl-70 were analyzed in serum samples obtained from healthy controls (n = 30), SSc patients (n = 320) and non-SSc connective-tissue disease patients (n = 100) using an Euroline Systemic Sclerosis Profile kit. RESULTS: SSc patients had increased prevalence of anti-RP11 (P = 0.032), anti-CENPB (P < 0.001), anti-CENPA (P = 0.001) and anti-Scl-70 (P < 0.001), but had decreased prevalence of anti-Ro-52 (P = 0.004), when compared to non-SSc CTDs. Furthermore, SSc patients had increased prevalence of anti-Ro-52 (P = 0.003), anti-CENPB (P = 0.034), anti-CENPA (P = 0.034) and anti-Scl-70 (P < 0.001), when compared to HCs. In addition, SSc patients with interstitial lung disease (ILD) had increased prevalence of anti-Ro-52 (P = 0.046) and anti-Scl-70 (P = 0.035), but had decreased prevalence of anti-CENPB (P < 0.001) and anti-CENPA (P < 0.001). Moreover, SSc patients with pulmonary arterial hypertension (PAH) had increased prevalence of anti-Ro-52 (P = 0.013) and decreased prevalence of anti-Scl-70 (P = 0.001). Anti-Ro-52 and anti-Scl-70 had increased values for predicting ILD in SSc patients, while anti-Ro-52 had increased values for predicting PAH in SSc patients. CONCLUSION: A commercial line immunoassay was used to evaluate the diagnostic value of autoantibodies in Chinese Han SSc patients. The results clearly indicate that the immunoblot assay has good diagnostic utility for SSc. Anti-Ro-52, anti-RP11, anti-CENPB, anti-CENPA and anti-Scl-70 are useful for diagnosing SSc in the Chinese Han population. Anti-Ro-52, anti-CENPB, anti-CENPA and anti-Scl-70 have a potential value for diagnosing ILD in SSc patients. Furthermore, anti-Ro-52 and anti-Scl-70 may be used to diagnose PAH in SSc patients. SN - 1873-3492 UR - https://www.unboundmedicine.com/medline/citation/30685360/Evaluation_of_a_commercial_immunoassay_for_autoantibodies_in_Chinese_Han_systemic_sclerosis_population_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0009-8981(19)30044-0 DB - PRIME DP - Unbound Medicine ER -